Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Genaera Corp.

Latest From Genaera Corp.

Antibiotic Drug Push By Administration Could Include BARDA Incubator

As NIH workshop discusses novel approaches to combatting antibiotic resistance from monoclonal antibodies to synthetic stool transplants and antimicrobial peptides, plans are underway to expand BARDA’s focus beyond biodefense.

BioPharmaceutical Clinical Trials

Stockwatch. Eyeballs or optical delusion?

The recent acquisition of the shares of Alcon that Novartis didn’t own for about $13 billion might have reinforced investors’ appetite for eye care-related pharmaceuticals (, 15 Dec 2010). However, Novartis’ consolidation of Alcon appeared more of a move to wholly own a separate business unit complete with sales force, a dominant position in soup-to-nuts eye care and sales of $6.5bn, than a focus on a particular new drug. On the other hand, Sanofi’s acquisition of the private company Fovea Pharmaceuticals SA (, 1 Oct 2009) marked a rare big pharmaceutical foray for an ophthalmology pipeline.

2010 Scrip 100 - Survivors of the shakeout

Crunched credit wiped out many biotech firms in 2009, yet some emerged from the wreckage leaner and stronger. How did they do it, asks Dr Sukaina Virji-Jeganathan.

Metabolic Disorders Cancer

Market Insight - Obesity: what next after the CB1 antagonists' failure?

The European regulator's recent decision to suspend sales of Sanofi-Aventis's Acomplia (rimonabant) came hot on the heels of setbacks with two other late-stage CB1 antagonist agents, and the developments have put the spotlight on obesity as a therapy area and made some observers question whether this is still a market potentially worth billions of dollars.

Metabolic Disorders Cardiovascular
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Magainin Pharmaceuticals Inc.
  • Ownership
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Genaera Corp.
  • Senior Management
  • John L Armstrong, Jr., Pres. & CEO
    Leanne M Kelly, SVP, CFO
    Michael J Gast, MD, PhD, EVP, CMO
  • Contact Info
  • Genaera Corp.
    Phone: (610) 941-4020
    5110 Campus Dr.
    Plymouth Meeting, PA 19462